Cluster-Based Immunotherapy for Patients with Recurrent Abortion Caused by Antiphospholipid Syndrome

• Main Authors: Ruifang Wang, Juanjuan Yu, Zhen Yan, Xiaolin Cheng, Jian Chen, Yunhong Guo
• Format: Article
• Language: English
• Published: Hindawi Limited 2021-01-01
• Series: Journal of Healthcare Engineering
• Online Access: http://dx.doi.org/10.1155/2021/4581900

In order to diagnose patients with pregnancy and antiphospholipid antibody syndrome, provide early treatment, and effectively reduce the pregnancy outcome of the abnormal pregnancy, the effect of antiphospholipid syndrome (APS) immunotherapy on the incidence of abortion was discussed based on clustering algorithm. We selected 62 cases of APS leading to recurrent miscarriage patients, in the early pregnancy injection of low molecular heparin, intravenous drip proprocyclin, and oral tactics, using B-ultrasound images to observe the pregnancy ending. The results show that the hormone levels in the two groups were different before treatment (P>0.05); after treatment, the HCG, E2, and P hormone levels in the two groups were significantly improved, and the HCG, E2, and P hormone levels in the observation group were significantly higher than those of the control group (P<0.05); the abortion rate of patients in the observation group was significantly lower than that of the control group (P<0.05); the antiphosphorus antibody of the study group was significantly higher than that of the control group. For APS patients, immunotherapy is effective. Antiphospholipid syndrome causes remarkable immunotherapy effect in patients with recurrent miscarriage, effectively improves the clinical symptoms of patients, improves antiprochemical antibody rosion, and improves the patient’s pregnancy outcomes, which is worth promoting.